Magenta Therapeutics falls on pausing blood cancer therapy trial after death of participant

Dianthus Therapeutics

25/01/2023 22:12

** Shares of drug developer Magenta Therapeutics Inc
 MGTA.O  fall ~23% to 38 cents after the bell, among top pct
losers across U.S. exchanges
    ** Co paused dosing in its early-to-mid stage trial of blood
cancer therapy MGTA-117 after the latest participant, dosed at
Cohort 3 level, experienced respiratory failure and cardiac
arrest resulting in death
    ** Co says known information has been reported to the U.S.
FDA as a suspected unexpected serious adverse reaction
    ** MGTA-117 was being studied to treat myeloid leukemia and
myelodysplastic syndrome, types of blood and bone marrow cancer 
    ** In Dec, co said it stopped dosing patients at the cohort
4 dosing level after dose-limiting toxicities were observed in
the second and third dosed participants
    ** Stock lost ~91% last year
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))